Benjamin P Howden

Summary

Affiliation: Austin Health
Country: Australia

Publications

  1. ncbi Accurate assessment of heterogeneous vancomycin-intermediate Staphylococcus aureus nasal carriage
    Patrick G P Charles
    Clin Infect Dis 41:1071-2; author reply 1072-3. 2005
  2. ncbi Evolution of multidrug resistance during Staphylococcus aureus infection involves mutation of the essential two component regulator WalKR
    Benjamin P Howden
    Department of Microbiology and Immunology, University of Melbourne, Victoria, Australia
    PLoS Pathog 7:e1002359. 2011
  3. ncbi Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility
    Benjamin P Howden
    Department of Infectious Diseases, Austin Hospital, Heidelberg, Victoria, Australia
    Clin Infect Dis 38:521-8. 2004
  4. ncbi Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications
    Benjamin P Howden
    Department of Infectious Diseases, Austin Health, Victoria, Australia
    Clin Microbiol Rev 23:99-139. 2010
  5. ncbi Genomic analysis reveals a point mutation in the two-component sensor gene graS that leads to intermediate vancomycin resistance in clinical Staphylococcus aureus
    Benjamin P Howden
    Department of Microbiology, Monash University, Wellington Rd, Clayton, Victoria, Australia
    Antimicrob Agents Chemother 52:3755-62. 2008
  6. ncbi Recognition and management of infections caused by vancomycin-intermediate Staphylococcus aureus (VISA) and heterogenous VISA (hVISA)
    B P Howden
    Infectious Disease Department, Austin Health, Heidelberg, Australia
    Intern Med J 35:S136-40. 2005
  7. ncbi Chronic falciparum malaria causing massive splenomegaly 9 years after leaving an endemic area
    Benjamin P Howden
    Austin Health, Melbourne, Vic
    Med J Aust 182:186-8. 2005
  8. ncbi Low-level vancomycin resistance in Staphylococcus aureus--an Australian perspective
    B P Howden
    Infectious Diseases Department, Austin Health, Melbourne, Australia
    Eur J Clin Microbiol Infect Dis 24:100-8. 2005
  9. ncbi Treatment and outcome of 104 hospitalized patients with legionnaires' disease
    B P Howden
    Department of Microbiology, Austin and Repatriation Medical Centre, Heidelberg, Victoria, Australia
    Intern Med J 33:484-8. 2003
  10. ncbi Two novel point mutations in clinical Staphylococcus aureus reduce linezolid susceptibility and switch on the stringent response to promote persistent infection
    Wei Gao
    Department of Microbiology, Monash University, Clayton, Victoria, Australia
    PLoS Pathog 6:e1000944. 2010

Collaborators

Detail Information

Publications45

  1. ncbi Accurate assessment of heterogeneous vancomycin-intermediate Staphylococcus aureus nasal carriage
    Patrick G P Charles
    Clin Infect Dis 41:1071-2; author reply 1072-3. 2005
  2. ncbi Evolution of multidrug resistance during Staphylococcus aureus infection involves mutation of the essential two component regulator WalKR
    Benjamin P Howden
    Department of Microbiology and Immunology, University of Melbourne, Victoria, Australia
    PLoS Pathog 7:e1002359. 2011
    ..aureus infections and demonstrates the role played by walKR to increase drug resistance, control metabolism and alter the virulence potential of this pathogen...
  3. ncbi Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility
    Benjamin P Howden
    Department of Infectious Diseases, Austin Hospital, Heidelberg, Victoria, Australia
    Clin Infect Dis 38:521-8. 2004
    ....
  4. ncbi Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications
    Benjamin P Howden
    Department of Infectious Diseases, Austin Health, Victoria, Australia
    Clin Microbiol Rev 23:99-139. 2010
    ..Given the subtleties of vancomycin susceptibility testing against S. aureus, it is imperative that diagnostic laboratories use well-standardized methods and have a framework for detecting reduced vancomycin susceptibility in S. aureus...
  5. ncbi Genomic analysis reveals a point mutation in the two-component sensor gene graS that leads to intermediate vancomycin resistance in clinical Staphylococcus aureus
    Benjamin P Howden
    Department of Microbiology, Monash University, Wellington Rd, Clayton, Victoria, Australia
    Antimicrob Agents Chemother 52:3755-62. 2008
    ..However, additional mutations are likely required to express the full VISA phenotype...
  6. ncbi Recognition and management of infections caused by vancomycin-intermediate Staphylococcus aureus (VISA) and heterogenous VISA (hVISA)
    B P Howden
    Infectious Disease Department, Austin Health, Heidelberg, Australia
    Intern Med J 35:S136-40. 2005
    ..Clinicians and diagnostic laboratories need to be aware of VISA and hVISA as a clinical problem, and consider aggressive surgical debridement and non-glycopeptide-based therapy where infections with such strains are suspected or proven...
  7. ncbi Chronic falciparum malaria causing massive splenomegaly 9 years after leaving an endemic area
    Benjamin P Howden
    Austin Health, Melbourne, Vic
    Med J Aust 182:186-8. 2005
    ..It should be considered in such patients with presentations possibly related to malaria, including splenomegaly, anaemia, or a long history of intermittent fevers and chills...
  8. ncbi Low-level vancomycin resistance in Staphylococcus aureus--an Australian perspective
    B P Howden
    Infectious Diseases Department, Austin Health, Melbourne, Australia
    Eur J Clin Microbiol Infect Dis 24:100-8. 2005
    ..Diagnostic laboratories and clinicians need to be aware of this resistance phenotype, to have procedures in place to detect the resistance, and to have strategies for managing patients with infections caused by resistant strains...
  9. ncbi Treatment and outcome of 104 hospitalized patients with legionnaires' disease
    B P Howden
    Department of Microbiology, Austin and Repatriation Medical Centre, Heidelberg, Victoria, Australia
    Intern Med J 33:484-8. 2003
    ..A large outbreak of legionnaires' disease associated with the Melbourne Aquarium occurred in April 2000...
  10. ncbi Two novel point mutations in clinical Staphylococcus aureus reduce linezolid susceptibility and switch on the stringent response to promote persistent infection
    Wei Gao
    Department of Microbiology, Monash University, Clayton, Victoria, Australia
    PLoS Pathog 6:e1000944. 2010
    ..These results reinforce the exquisite adaptability of S. aureus and show how subtle molecular changes cause major alterations in bacterial behaviour, as well as highlighting potential weaknesses of current antibiotic treatment regimens...
  11. ncbi A sustained hospital outbreak of vancomycin-resistant Enterococcus faecium bacteremia due to emergence of vanB E. faecium sequence type 203
    Paul D R Johnson
    Department of Infectious Diseases and Microbiology, Austin Health, Monash University, Melbourne, Victoria, Australia
    J Infect Dis 202:1278-86. 2010
    ..A significant increase in the rate of vancomycin-resistant Enterococcus faecium (VREfm) bacteremia at our health service, despite improved infection control, prompted us to investigate the cause...
  12. ncbi Isolates with low-level vancomycin resistance associated with persistent methicillin-resistant Staphylococcus aureus bacteremia
    Benjamin P Howden
    Department of Microbiology, Monash University, Clayton, 3800 Victoria, Australia
    Antimicrob Agents Chemother 50:3039-47. 2006
    ..These clinically derived pairs of isolates will be a useful resource to elucidate the genetic mechanism of resistance in hVISA/VISA strains...
  13. ncbi Serine/threonine phosphatase Stp1 contributes to reduced susceptibility to vancomycin and virulence in Staphylococcus aureus
    David R Cameron
    Department of Microbiology, Monash University, Melbourne, Australia
    J Infect Dis 205:1677-87. 2012
    ..Stp1 provides a new link between vancomycin susceptibility and virulence in S. aureus...
  14. ncbi Different bacterial gene expression patterns and attenuated host immune responses are associated with the evolution of low-level vancomycin resistance during persistent methicillin-resistant Staphylococcus aureus bacteraemia
    Benjamin P Howden
    Australian Bacterial Pathogenesis Program, Department of Microbiology, Monash University, Clayton, Victoria, Australia
    BMC Microbiol 8:39. 2008
    ..Based on the transcriptome results multiple genes were sequenced and innate immune system stimulation was assessed in the VSSA and hVISA/VISA pairs...
  15. ncbi Comparative analysis of the first complete Enterococcus faecium genome
    Margaret M C Lam
    Department of Microbiology and Immunology, University of Melbourne, Victoria, Australia
    J Bacteriol 194:2334-41. 2012
    ..A complete E. faecium genome will be a useful resource to assist our understanding of this emerging nosocomial pathogen...
  16. ncbi Clinical features associated with bacteremia due to heterogeneous vancomycin-intermediate Staphylococcus aureus
    Patrick G P Charles
    Department of Infectious Diseases, Austin Health, Heidelberg, Victoria, Australia
    Clin Infect Dis 38:448-51. 2004
    ..001), and initially low serum vancomycin levels (P=.006). These clinical markers of hVISA bacteremia may help focus diagnostic efforts and treatment...
  17. ncbi Antibiotic choice may not explain poorer outcomes in patients with Staphylococcus aureus bacteremia and high vancomycin minimum inhibitory concentrations
    Natasha E Holmes
    Department of Infectious Diseases, Austin Health, Heidelberg, Australia
    J Infect Dis 204:340-7. 2011
    ..There are concerns about reduced efficacy of vancomycin in patients with Staphylococcus aureus bacteremia (SAB), especially when the minimum inhibitory concentration (MIC) nears the upper limit of the susceptible range...
  18. ncbi Daptomycin non-susceptibility in vancomycin-intermediate Staphylococcus aureus (VISA) and heterogeneous-VISA (hVISA): implications for therapy after vancomycin treatment failure
    Peter G Kelley
    Department of Microbiology, Austin Health, Heidelberg, Victoria, Australia
    J Antimicrob Chemother 66:1057-60. 2011
    ....
  19. ncbi Treating Gram-positive infections: vancomycin update and the whys, wherefores and evidence base for continuous infusion of anti-Gram-positive antibiotics
    Kyra Chua
    Department of Infectious Diseases, Australia
    Curr Opin Infect Dis 22:525-34. 2009
    ..This review summarizes the current literature concerning the use of vancomycin and the role of continuous infusion antimicrobials for treatment of Gram-positive infections...
  20. ncbi The dominant Australian community-acquired methicillin-resistant Staphylococcus aureus clone ST93-IV [2B] is highly virulent and genetically distinct
    Kyra Y L Chua
    Department of Microbiology, Monash University, Clayton, Australia
    PLoS ONE 6:e25887. 2011
    ....
  21. ncbi Relationship between vancomycin-resistant Staphylococcus aureus, vancomycin-intermediate S. aureus, high vancomycin MIC, and outcome in serious S. aureus infections
    Natasha E Holmes
    Austin Centre for Infection Research, Department of Infectious Diseases, Austin Health, Heidelberg, Victoria, USA
    J Clin Microbiol 50:2548-52. 2012
    ..aureus and discusses practical issues for the diagnostic laboratory in testing and interpreting vancomycin susceptibility for S. aureus infections...
  22. ncbi Complete genome sequence of Staphylococcus aureus strain JKD6159, a unique Australian clone of ST93-IV community methicillin-resistant Staphylococcus aureus
    Kyra Chua
    Department of Microbiology, Monash University, Melbourne, Victoria, Australia
    J Bacteriol 192:5556-7. 2010
    ..This isolate is a representative of the most common Australian clone of cMRSA that is more distantly related to the previously sequenced genomes of S. aureus...
  23. ncbi Evaluation of the Xpertâ„¢ MRSA/SA Blood Culture assay for the detection of Staphylococcus aureus including strains with reduced vancomycin susceptibility from blood culture specimens
    Peter G Kelley
    Microbiology, Austin Health, Victoria, Australia
    Diagn Microbiol Infect Dis 70:404-7. 2011
    ..Among 28 heterogeneous vancomycin-intermediate S. aureus (hVISA)/VISA spiked BCs, the assay correctly identified 84.6% VISA and 80% hVISA isolates as MRSA...
  24. ncbi Complete genome sequence of Staphylococcus aureus strain JKD6008, an ST239 clone of methicillin-resistant Staphylococcus aureus with intermediate-level vancomycin resistance
    Benjamin P Howden
    Department of Microbiology and Immunology, University of Melbourne, Parkville 3010, Victoria, Australia
    J Bacteriol 192:5848-9. 2010
    ..aureus that demonstrates intermediate-level vancomycin resistance. The strain, named JKD6008, belongs to multilocus sequence type 239 and was isolated from the bloodstream of a patient in New Zealand in 2003...
  25. ncbi Antimicrobial resistance: Not community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA)! A clinician's guide to community MRSA - its evolving antimicrobial resistance and implications for therapy
    Kyra Chua
    Infectious Diseases, Austin Health, Heidelberg, Victoria, Australia
    Clin Infect Dis 52:99-114. 2011
    ..Continued monitoring of global epidemiology and emerging drug resistance data is critical for the effective management of these infections...
  26. ncbi Good clinical outcomes but high rates of adverse reactions during linezolid therapy for serious infections: a proposed protocol for monitoring therapy in complex patients
    Emma Bishop
    Infectious Diseases Department, Austin Health, Studley Rd, Heidelberg, Victoria 3084, Australia
    Antimicrob Agents Chemother 50:1599-602. 2006
    ....
  27. ncbi Dumb and dumber--the potential waste of a useful antistaphylococcal agent: emerging fusidic acid resistance in Staphylococcus aureus
    Benjamin P Howden
    Infectious Diseases Department, Austin Health, Heidelberg, Victoria, 3084, Australia
    Clin Infect Dis 42:394-400. 2006
    ..Ensuring that systemic fusidic acid is always used in combination and that the use of topical fusidic acid is either abolished or restricted will be vital if we are to prevent the loss of this potentially useful agent...
  28. ncbi In vitro pharmacodynamics of colistin against multidrug-resistant Klebsiella pneumoniae
    Anima Poudyal
    Facility for Anti Infective Drug Development and Innovation, Monash Institute of Pharmaceutical Sciences, Monash University, Vic, Australia
    J Antimicrob Chemother 62:1311-8. 2008
    ..Resistance to colistin is emerging in multidrug-resistant Gram-negative bacteria and no solid pharmacodynamic data are available for colistin against Klebsiella pneumoniae...
  29. ncbi Continuous-infusion penicillin home-based therapy for serious infections due to penicillin-susceptible pathogens
    Aaron L Walton
    Infectious Diseases Department, Monash Medical Centre, Clayton, Australia
    Int J Antimicrob Agents 29:544-8. 2007
    ..Thus, CI penicillin is feasible for the home-based treatment of a variety of deep-seated infections with minimal toxicity...
  30. ncbi Comparative study of selective chromogenic (chromID VRE) and bile esculin agars for isolation and identification of vanB-containing vancomycin-resistant enterococci from feces and rectal swabs
    E A Grabsch
    Microbiology Department, Austin Health, Melbourne, Australia
    J Clin Microbiol 46:4034-6. 2008
    ..However, cIDVRE detected significantly more VRE at 24 h (39.3% versus 21.3%, P = 0.003), and its use may facilitate the timely implementation of infection control procedures...
  31. ncbi The interface between antibiotic resistance and virulence in Staphylococcus aureus and its impact upon clinical outcomes
    David R Cameron
    Department of Microbiology, Monash University, Melbourne, Australia
    Clin Infect Dis 53:576-82. 2011
    ....
  32. ncbi The rise of antimicrobial resistance: a clear and present danger
    Natasha E Holmes
    Austin Centre for Infection Research, Department of Infectious Diseases, Austin Health, Heidelberg VIC 3084, Australia
    Expert Rev Anti Infect Ther 9:645-8. 2011
    ..This meeting report focuses on two key areas of antimicrobial resistance: community-associated methicillin-resistant Staphylococcus aureus and resistance in Gram-negative organisms...
  33. ncbi Treatment of Staphylococcus aureus infections: new issues, emerging therapies and future directions
    Emma J Bishop
    Austin Health, Infectious Diseases Department, Studley Road, Heidelberg, 3084, Victoria, Australia
    Expert Opin Emerg Drugs 12:1-22. 2007
    ..aureus infections, and considers the safety profiles and likely impact on present treatment standards of novel agents either undergoing clinical development or emerging onto the market...
  34. ncbi Prospective comparison of the clinical impacts of heterogeneous vancomycin-intermediate methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-susceptible MRSA
    K C Horne
    Infectious Diseases Department, Austin Hospital, Austin Health, P O Box 5555 Studley Rd, Heidelberg, Vic, Australia
    Antimicrob Agents Chemother 53:3447-52. 2009
    ....
  35. ncbi Coxiella burnetii endocarditis after Q fever vaccination
    Jason A Trubiano
    Department of Infectious Diseases, Austin Health, Heidelberg, Vic, Australia
    J Med Microbiol 61:1775-9. 2012
    ..Here, we present a case of Q fever native valve endocarditis that developed in a young man despite prior vaccination. Definitive diagnosis was difficult and required C. burnetii-specific PCR testing...
  36. ncbi Mycolactone gene expression is controlled by strong SigA-like promoters with utility in studies of Mycobacterium ulcerans and buruli ulcer
    Nicholas J Tobias
    Department of Microbiology, Monash University, Clayton, Victoria, Australia
    PLoS Negl Trop Dis 3:e553. 2009
    ..ulcerans-GFP, a strain in which fluorescence and toxin gene expression are linked, thus providing a tool for studying Buruli ulcer pathogenesis and potential transmission to humans...
  37. ncbi 5: Hospital-in-the-home treatment of infectious diseases
    Benjamin P Howden
    Microbiology Department, Austin and Repatriation Medical Centre, Melbourne, Vic
    Med J Aust 176:440-5. 2002
    ..6. Appropriate use of HITH leads to improved patient and carer satisfaction, efficient in-hospital bed use and possibly some financial efficiencies. Not all patients receiving intravenous antibiotics need to be in hospital..
  38. ncbi New aspirations: the debate on aspiration pneumonia treatment guidelines
    Jason C Kwong
    Austin Health, Melbourne, Vic
    Med J Aust 195:380-1. 2011
    ..Use of metronidazole may be appropriate in patients with aspiration pneumonia and evidence of a lung abscess, necrotising pneumonia, putrid sputum or severe periodontal disease...
  39. ncbi The efficacy of continuous infusion flucloxacillin in home therapy for serious staphylococcal infections and cellulitis
    B P Howden
    Department of Infectious Diseases, Austin and Repatriation Medical Centre, Studley Road, Heidelberg, Victoria 3084, Australia
    J Antimicrob Chemother 48:311-4. 2001
    ..The treatment was well tolerated and resulted in cure or adequate suppression of infection in 27 of 28 (96%) patients in the serious MSSA infection group, and in 24 of 26 (92%) patients in the cellulitis group...
  40. ncbi Comparison of the Xpert methicillin-resistant Staphylococcus aureus (MRSA) assay, BD GeneOhm MRSA assay, and culture for detection of nasal and cutaneous groin colonization by MRSA
    P G Kelley
    Infectious Diseases Department, Austin Health, Studley Rd, Heidelberg, Victoria, Australia 3084
    J Clin Microbiol 47:3769-72. 2009
    ..0% versus 84.8%, respectively) and specificities (93.8% versus 92.7%, respectively). Combined PCR assays provide a rapid and more-complete assessment of colonization at a cost similar to that of single-site analysis...
  41. ncbi Successful control of disseminated Scedosporium prolificans infection with a combination of voriconazole and terbinafine
    B P Howden
    Department of Infectious Diseases, The Alfred Hospital, Commercial Road, Prahran, Melbourne, Victoria 3181, Australia
    Eur J Clin Microbiol Infect Dis 22:111-3. 2003
    ..Antifungal synergy testing and combination therapy should be considered in cases of disseminated infection with Scedosporium prolificans...
  42. ncbi Improved outcomes with linezolid for methicillin-resistant Staphylococcus aureus infections: better drug or reduced vancomycin susceptibility?
    Benjamin P Howden
    Antimicrob Agents Chemother 49:4816; author reply 4816-7. 2005
  43. ncbi Failure of vancomycin for treatment of methicillin-resistant Staphylococcus aureus infections
    Benjamin P Howden
    Clin Infect Dis 39:1544; author reply 1544-5. 2004
  44. ncbi Staphylococcus aureus: a guide for the perplexed
    Paul D R Johnson
    Med J Aust 184:374-5. 2006
    ..The differences between community-acquired and health care-associated MRSA explained...
  45. ncbi Community and health-care associated non-multiresistant methicillin-resistant Staphylococcus aureus in Victoria
    Benjamin P Howden
    Med J Aust 183:548. 2005